Novo Nordisk faces slowing semaglutide momentum as new obesity contenders, including GPCR's aleniglipron, push the ...
Zacks Investment Research on MSN
NVO down 42% year to date: Is this an indication to sell the stock?
Novo Nordisk NVO has stumbled through 2025, with its shares down 41.5% year to date despite finally resolving U.S. supply constraints for its semaglutide-based GLP-1 blockbusters — Ozempic for type II ...
Can Novo Nordisk get its comeback going in 2026? Let's discuss two things that could materialize for the company next year ...
A federal judicial panel said Monday it would centralize a growing number of lawsuits against Novo Nordisk and Eli Lilly ...
Novo Nordisk A/S said its high-dose version of blockbuster Wegovy has been cleared by the European Union’s drug advisory board, opening the way for use of a shot that delivers more weight loss than ...
TipRanks on MSN
Novo Nordisk’s CagriSema study: A potential breakthrough for chronic kidney disease and diabetes
Novo Nordisk ($NVO) announced an update on their ongoing clinical study. Study Overview: Novo Nordisk recently completed a study titled ‘Efficacy ...
An expert panel of the EU drug regulator, the European Medicines Agency (EMA), endorsed seven new medicines for approval this ...
Americans without health insurance could be paying more than 10 times as much for the weight-loss drugs.
Data from Structure Therapeutics and WAVE Life Sciences show that threats to the incumbents’ dominance are on the way.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback